BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Kargiotis K, Athyros VG, Giouleme O, Katsiki N, Katsiki E, Anagnostis P, Boutari C, Doumas M, Karagiannis A, Mikhailidis DP. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol 2015; 21(25): 7860-7868 [PMID: 26167086 DOI: 10.3748/wjg.v21.i25.7860]
URL: https://www.wjgnet.com/1948-9358/full/v21/i25/7860.htm
Number Citing Articles
1
Nahum Méndez-Sánchez, Shreya C. Pal, Jacqueline Córdova-Gallardo. How far are we from an approved drug for nonalcoholic steatohepatitis?Expert Opinion on Pharmacotherapy 2023; 24(9): 1021 doi: 10.1080/14656566.2023.2206953
2
Vasilios G. Athyros, Niki Katsiki, Michael Doumas. Lipid association of India (LAI) expert consensus statement: part 2, specific patient categoriesClinical Lipidology 2018; 13(1): 1 doi: 10.1080/17584299.2017.1411068
3
Cheng Han Ng, Margaret LP Teng, Nicholas WS Chew, Kai En Chan, Jie Ning Yong, Jingxuan Quek, Darren Jun Hao Tan, Wen Hui Lim, Gabriel Sheng Jie Lee, Jessica Wong, Apichat Kaewdech, Daniel Q Huang, Jiongwei Wang, Mark Y Chan, Mazen Noureddin, Mohammad Shadab Siddiqui, Arun Sanyal, Mark Muthiah. Statins decrease overall mortality and cancer related mortality but are underutilized in NAFLD: a longitudinal analysis of 12,538 individualsExpert Review of Gastroenterology & Hepatology 2022; 16(9): 895 doi: 10.1080/17474124.2022.2119128
4
Feliciano Chanana Paquissi. Immune Imbalances in Non-Alcoholic Fatty Liver Disease: From General Biomarkers and Neutrophils to Interleukin-17 Axis Activation and New Therapeutic TargetsFrontiers in Immunology 2016; 7 doi: 10.3389/fimmu.2016.00490
5
Katsutoshi Tokushige, Kenichi Ikejima, Masafumi Ono, Yuichiro Eguchi, Yoshihiro Kamada, Yoshito Itoh, Norio Akuta, Masato Yoneda, Motoh Iwasa, Masashi Yoneda, Motoyuki Otsuka, Nobuharu Tamaki, Tomomi Kogiso, Hiroto Miwa, Kazuaki Chayama, Nobuyuki Enomoto, Tooru Shimosegawa, Tetsuo Takehara, Kazuhiko Koike. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020Journal of Gastroenterology 2021; 56(11): 951 doi: 10.1007/s00535-021-01796-x
6
Ramy Younes, Elisabetta Bugianesi. The Impact of Metabolic Syndrome on the Outcome of NASH: Cirrhosis, Hepatocellular Carcinoma, and MortalityCurrent Hepatology Reports 2018; 17(4): 336 doi: 10.1007/s11901-018-0422-x
7
Pavel Kraml. Lipid-lowering therapy in selected specific groups of patientsMedicína pro praxi 2020; 17(3): 151 doi: 10.36290/med.2020.029
8
Vasiliki Venetsanaki, Stergios A. Polyzos. Menopause and Non-Alcoholic Fatty Liver Disease: A Review Focusing on Therapeutic PerspectivesCurrent Vascular Pharmacology 2019; 17(6): 546 doi: 10.2174/1570161116666180711121949
9
Jaime Bosch, Jordi Gracia-Sancho, Juan G Abraldes. Cirrhosis as new indication for statinsGut 2020; 69(5): 953 doi: 10.1136/gutjnl-2019-318237
10
И.Р. Агабабян, Ш.Ш. Садыкова. Pleyotropic Effects of Statins Non-Alcoholic Fat Disease of the Liver Non-Alcoholic SteatohepatitisРецепт 2022; (2): 194 doi: 10.34883/PI.2022.25.2.006
11
Manal F. Abdelmalek. The clinical and economic burden of NAFLD: time to turn the tideNature Reviews Gastroenterology & Hepatology 2016; 13(12): 685 doi: 10.1038/nrgastro.2016.178
12
Konstantinos P. Imprialos, Konstantinos Stavropoulos, Michael Doumas, Anastasia Skalkou, Ioanna Zografou, Vasilios G. Athyros. The potential role of statins in treating liver diseaseExpert Review of Gastroenterology & Hepatology 2018; 12(4): 331 doi: 10.1080/17474124.2018.1439379
13
Stergios A. Polyzos, Eun Seok Kang, Chrysoula Boutari, Eun-Jung Rhee, Christos S. Mantzoros. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitisMetabolism 2020; 111: 154203 doi: 10.1016/j.metabol.2020.154203
14
N Katsiki, Td Filippatos, C Vlachopoulos, D Panagiotakos, H Milionis, A Tselepis, A Garoufi, L Rallidis, D Richter, T Nomikos, G Kolovou, K Kypreos, C Chrysohoou, K Tziomalos, I Skoumas, I Koutagiar, A Attilakos, M Papagianni, C Boutari, V Kotsis, C Pitsavos, M Elisaf, K Tsioufis, E Liberopoulos. Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023Atherosclerosis Plus 2024; 55: 74 doi: 10.1016/j.athplu.2024.01.004
15
Hersh Shroff, Lisa B. VanWagner. Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and ManagementCurrent Hepatology Reports 2020; 19(3): 315 doi: 10.1007/s11901-020-00530-0
16
Janet Lo, Michael T. Lu, Elli A. Kim, Eric Nou, Travis R. Hallett, Jakob Park, Udo Hoffmann, Steven K. Grinspoon. Statin Effects to Reduce Hepatosteatosis as Measured by Computed Tomography in Patients With Human Immunodeficiency VirusOpen Forum Infectious Diseases 2016; 3(2) doi: 10.1093/ofid/ofw062
17
Suguru Ikeda, Takaaki Sugihara, Takuya Kihara, Yukako Matsuki, Takakazu Nagahara, Tomoaki Takata, Sonoko Kitao, Tsuyoshi Okura, Kazuhiro Yamamoto, Hajime Isomoto. Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-UpDiagnostics 2021; 11(12): 2316 doi: 10.3390/diagnostics11122316
18
Emir Muzurović, Dimitri P. Mikhailidis, Christos Mantzoros. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular riskMetabolism 2021; 119: 154770 doi: 10.1016/j.metabol.2021.154770
19
Sonali Paul, Michael Charlton. Surgical Issues in NASH: Bariatric Surgery and Liver TransplantationCurrent Hepatology Reports 2018; 17(4): 367 doi: 10.1007/s11901-018-0429-3
20
Maryam Mahjoubin-Tehran, Antonio De Vincentis, Dimitri P. Mikhailidis, Stephen L. Atkin, Christos S. Mantzoros, Tannaz Jamialahmadi, Amirhossein Sahebkar. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosisMolecular Metabolism 2021; 50: 101049 doi: 10.1016/j.molmet.2020.101049
21
Farah Ahsan, Federico Oliveri, Harshit K Goud, Zainab Mehkari, Lubna Mohammed, Moiz Javed, Aldanah Althwanay, Ian H Rutkofsky. Pleiotropic Effects of Statins in the Light of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic SteatohepatitisCureus 2020;  doi: 10.7759/cureus.10446
22
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, Marlene Chakhtoura, Michael A. Hill, Dimitri P. Mikhailidis, Christos S. Mantzoros, Ali Eid. Steatotic Liver Disease: Pathophysiology and Emerging PharmacotherapiesPharmacological Reviews 2024; 76(3): 454 doi: 10.1124/pharmrev.123.001087
23
Niki Katsiki, Dimitri P Mikhailidis. Lipids: a personal view of the past decadeHormones 2018; 17(4): 461 doi: 10.1007/s42000-018-0058-9
24
Vasilios G. Athyros, Stergios A. Polyzos, Jiannis Kountouras, Niki Katsiki, Panagiotis Anagnostis, Michael Doumas, Christos S. Mantzoros. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the BlockCurrent Vascular Pharmacology 2020; 18(2): 172 doi: 10.2174/1570161117666190405164313
25
Panagiotis Anagnostis, Konstantina Vaitsi, Panagiota Kleitsioti, Chrysanthi Mantsiou, Konstantinos Pavlogiannis, Vasilios G. Athyros, Dimitri P. Mikhailidis, Dimitrios G. Goulis. Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trialsEndocrine 2020; 69(2): 249 doi: 10.1007/s12020-020-02302-8
26
Christian L. Horn, Amilcar L. Morales., Christopher Savard, Geoffrey C Farrell, George N. Ioannou. Role of Cholesterol‐Associated Steatohepatitis in the Development of NASHHepatology Communications 2022; 6(1): 12 doi: 10.1002/hep4.1801
27
Vasilios G. Athyros, Niki Katsiki, Dimitri P. Mikhailidis. Letter to the editor: Treating nonalcoholic fatty liver disease with statins. Are all statins equal?American Journal of Physiology-Gastrointestinal and Liver Physiology 2017; 312(6): G681 doi: 10.1152/ajpgi.00101.2017
28
Dilek Yazıcı, Selin Çakmak Demir, Havva Sezer. Obesity and LipotoxicityAdvances in Experimental Medicine and Biology 2024; 1460: 391 doi: 10.1007/978-3-031-63657-8_14
29
George N. Ioannou, Charles S. Landis, Ga‐Young Jin, W. Geoffrey Haigh, Geoffrey C. Farrell, Rahul Kuver, Sum P. Lee, Christopher Savard. Cholesterol Crystals in Hepatocyte Lipid Droplets Are Strongly Associated With Human Nonalcoholic SteatohepatitisHepatology Communications 2019; 3(6): 776 doi: 10.1002/hep4.1348
30
Vasilios Gabriel Athyros. Multifactorial treatment of diabetic patients with cardiovascular disease to maximize resultsJournal of Diabetes and its Complications 2021; 35(6): 107904 doi: 10.1016/j.jdiacomp.2021.107904
31
Niki Katsiki, Dimitri P. Mikhailidis, Christos S. Mantzoros. Non-alcoholic fatty liver disease and dyslipidemia: An updateMetabolism 2016; 65(8): 1109 doi: 10.1016/j.metabol.2016.05.003
32
Francesca Cortese, Michele Gesualdo, Annamaria Cortese, Santa Carbonara, Fiorella Devito, Annapaola Zito, Gabriella Ricci, Pietro Scicchitano, Marco Matteo Ciccone. Rosuvastatin: Beyond the cholesterol-lowering effectPharmacological Research 2016; 107: 1 doi: 10.1016/j.phrs.2016.02.012
33
Vasilios G. Athyros, Theodore K. Alexandrides, Helen Bilianou, Evangelos Cholongitas, Michael Doumas, Emmanuel S. Ganotakis, John Goudevenos, Moses S. Elisaf, Georgios Germanidis, Olga Giouleme, Asterios Karagiannis, Charalambos Karvounis, Niki Katsiki, Vasilios Kotsis, Jannis Kountouras, Evangelos Liberopoulos, Christos Pitsavos, Stergios Polyzos, Loukianos S. Rallidis, Dimitrios Richter, Apostolos G. Tsapas, Alexandros D. Tselepis, Konstantinos Tsioufis, Konstantinos Tziomalos, Themistoklis Tzotzas, Themistoklis G. Vasiliadis, Charalambos Vlachopoulos, Dimitri P. Mikhailidis, Christos Mantzoros. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel StatementMetabolism 2017; 71: 17 doi: 10.1016/j.metabol.2017.02.014
34
Joseph M Pappachan, Shithu Babu, Babu Krishnan, Nishal C Ravindran. Non-alcoholic Fatty Liver Disease: A Clinical UpdateJournal of Clinical and Translational Hepatology 2017; (XX): XX doi: 10.14218/JCTH.2017.00013
35
Roberta de Pádua Borges, Nathália Abi Habib Degobi, Marcello Casaccia Bertoluci. Choosing statins: a review to guide clinical practiceArchives of Endocrinology and Metabolism 2020;  doi: 10.20945/2359-3997000000306
36
Vasilios G. Athyros, Niki Katsiki, Asterios Karagiannis. Off target effects of statins shape total mortality?Journal of Drug Assessment 2016; 5(1): 4 doi: 10.3109/21556660.2016.1168302
37
Pakkapon Rattanachaisit, Paweena Susantitaphong, Kessarin Thanapirom, Roongruedee Chaiteerakij, Piyawat Komolmit, Pisit Tangkijvanich, Sombat Treeprasertsuk. Statin use and histopathological change in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysisAsian Biomedicine 2018; 12(1): 3 doi: 10.1515/abm-2018-0026
38
Yongfeng Song, Junjun Liu, Ke Zhao, Ling Gao, Jiajun Zhao. Cholesterol-induced toxicity: An integrated view of the role of cholesterol in multiple diseasesCell Metabolism 2021; 33(10): 1911 doi: 10.1016/j.cmet.2021.09.001
39
Vasilios G. Athyros, Niki Katsiki, Dimitri P. Mikhailidis. Clinical benefit of statin treatment on patients with non-alcoholic fatty liver disease or steatohepatitisClinics and Research in Hepatology and Gastroenterology 2022; 46(4): 101842 doi: 10.1016/j.clinre.2021.101842
40
Weiwei Dai, Baohong Xu, Peng Li, Junhua Weng. Statins for the Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: A Systematic Review and Meta-AnalysisAmerican Journal of Therapeutics 2023; 30(1): e17 doi: 10.1097/MJT.0000000000001499
41
Samarth Siddharth Patel, Mohammad Shadab Siddiqui. Current and Emerging Therapies for Non-alcoholic Fatty Liver DiseaseDrugs 2019; 79(1): 75 doi: 10.1007/s40265-018-1040-1
42
Nguyen Pham, Jihane N. Benhammou. Statins in Chronic Liver Disease: Review of the Literature and Future RoleSeminars in Liver Disease 2024; 44(02): 191 doi: 10.1055/a-2319-0694
43
Niki Katsiki, Genovefa Kolovou, Pablo Perez-Martinez, Dimitri P. Mikhailidis. Dyslipidaemia in the elderly: to treat or not to treat?Expert Review of Clinical Pharmacology 2018; 11(3): 259 doi: 10.1080/17512433.2018.1425138
44
Ricardo Amorim, Pedro Soares, Daniel Chavarria, Sofia Benfeito, Fernando Cagide, José Teixeira, Paulo J. Oliveira, Fernanda Borges. Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunitiesEuropean Journal of Medicinal Chemistry 2024; 277: 116723 doi: 10.1016/j.ejmech.2024.116723
45
Won Dong Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim. Combined use of rosuvastatin and ezetimibe improves hepatic steatosis in patients with dyslipidemiaEuropean Journal of Gastroenterology & Hepatology 2020; 32(12): 1538 doi: 10.1097/MEG.0000000000001665
46
Nicholas W.S. Chew, Mark D. Muthiah, Arun J. Sanyal. Cardiovascular Endocrinology and Metabolism2023; : 137 doi: 10.1016/B978-0-323-99991-5.00003-6
47
Vasilios G. Athyros, Niki Katsiki, Dimitri P. Mikhailidis. NAFLD and StatinsDigestive Diseases and Sciences 2020; 65(10): 3052 doi: 10.1007/s10620-020-06505-x
48
D. van der Graaff, W.J. Kwanten, S.M. Francque. The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitisMedical Hypotheses 2019; 122: 188 doi: 10.1016/j.mehy.2018.11.014
49
Mazen Noureddin, Alice Zhang, Rohit Loomba. Promising therapies for treatment of nonalcoholic steatohepatitisExpert Opinion on Emerging Drugs 2016; 21(3): 343 doi: 10.1080/14728214.2016.1220533
50
Joost Boeckmans, Alessandra Natale, Karolien Buyl, Vera Rogiers, Joery De Kock, Tamara Vanhaecke, Robim M. Rodrigues. Human-based systems: Mechanistic NASH modelling just around the corner?Pharmacological Research 2018; 134: 257 doi: 10.1016/j.phrs.2018.06.029
51
Bubu A. Banini, Arun J. Sanyal. Current and future pharmacologic treatment of nonalcoholic steatohepatitisCurrent Opinion in Gastroenterology 2017; 33(3): 134 doi: 10.1097/MOG.0000000000000356
52
Chattraya Ngamlerst, Arunwan Udomkasemsab, Ratchanee Kongkachuichai, Karunee Kwanbunjan, Chaowanee Chupeerach, Pattaneeya Prangthip. The potential of antioxidant-rich Maoberry (Antidesma bunius) extract on fat metabolism in liver tissues of rats fed a high-fat dietBMC Complementary and Alternative Medicine 2019; 19(1) doi: 10.1186/s12906-019-2716-0
53
Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim. Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseasesClinical and Molecular Hepatology 2022; 28(3): 425 doi: 10.3350/cmh.2022.0186
54
C. Moctezuma-Velázquez. Current treatment for non-alcoholic fatty liver diseaseRevista de Gastroenterología de México (English Edition) 2018; 83(2): 125 doi: 10.1016/j.rgmxen.2018.05.014
55
Sven M. Francque, W. J. Kwanten, D. van der Graaff. Portal Hypertension in NASH: Is It Different from Other Aetiologies?Current Hepatology Reports 2019; 18(2): 134 doi: 10.1007/s11901-019-00459-z
56
Diana Barb, Kenneth Cusi. Reply to “statins and non-alcoholic steatohepatitis”Metabolism 2017; 66: e3 doi: 10.1016/j.metabol.2016.10.004
57
Shiqin Zhang, Xiaoling Ren, Bingzheng Zhang, Tian Lan, Bing Liu. A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of ActionMolecules 2024; 29(8): 1859 doi: 10.3390/molecules29081859
58
Connie B. Newman, David Preiss, Jonathan A. Tobert, Terry A. Jacobson, Robert L. Page, Larry B. Goldstein, Clifford Chin, Lisa R. Tannock, Michael Miller, Geetha Raghuveer, P. Barton Duell, Eliot A. Brinton, Amy Pollak, Lynne T. Braun, Francine K. Welty. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart AssociationArteriosclerosis, Thrombosis, and Vascular Biology 2019; 39(2) doi: 10.1161/ATV.0000000000000073
59
B. V. M. Dasari, A. Pathanki, J. Hodson, K. J. Roberts, R. Marudanayagam, D. F. Mirza, J. Isaac, R. P. Sutcliffe, P. Muiesan. Propensity-matched analysis of the influence of perioperative statin therapy on outcomes after liver resectionBJS Open 2019; 3(4): 509 doi: 10.1002/bjs5.50155
60
Ke Pei, Ting Gui, Dongfang Kan, Huichao Feng, Yanqiang Jin, Ying Yang, Qian Zhang, Ziwei Du, Zhibo Gai, Jibiao Wu, Yunlun Li. An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver DiseaseBioMed Research International 2020; 2020: 1 doi: 10.1155/2020/4020249
61
Somaya Albhaisi, Arun J. Sanyal. Comprehensive Pharmacology2022; : 214 doi: 10.1016/B978-0-12-820472-6.00121-3
62
Xiaoyan Zhang, Jingxin Li, Tiancai Liu, Min Zhao, Baozhu Liang, Hong Chen, Zhen Zhang, Ihtisham Bukhari. Identification of Key Biomarkers and Immune Infiltration in Liver Tissue after Bariatric SurgeryDisease Markers 2022; 2022: 1 doi: 10.1155/2022/4369329
63
Vasilios G. Athyros, Niki Katsiki, Asterios Karagiannis, Dimitri P. Mikhailidis. Statins and non-alcoholic steatohepatitisJournal of Hepatology 2016; 64(1): 241 doi: 10.1016/j.jhep.2015.09.021
64
Asahiro Morishita, Kyoko Oura, Kei Takuma, Mai Nakahara, Tomoko Tadokoro, Koji Fujita, Joji Tani, Tingting Shi, Takashi Himoto, Miwa Tatsuta, Akio Moriya, Tomonori Senoo, Akemi Tsutsui, Takuya Nagano, Koichi Takaguchi, Masafumi Ono, Tsutomu Masaki. Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter studyHepatology International 2023; 17(3): 606 doi: 10.1007/s12072-022-10453-1
65
Kaveh Hajifathalian, Zaid Tafesh, Russell Rosenblatt, Sonal Kumar, Edwin A. Homan, Reem Z. Sharaiha, David E. Cohen, Robert S. Brown, Brett E. Fortune. Effect of Statin Use on Cancer-related Mortality in Nonalcoholic Fatty Liver DiseaseJournal of Clinical Gastroenterology 2022; 56(2): 173 doi: 10.1097/MCG.0000000000001503
66
Xianhua Liao, Qianqian Ma, Tingfeng Wu, Congxiang Shao, Yansong Lin, Yanhong Sun, Shiting Feng, Wei Wang, Junzhao Ye, Bihui Zhong. Lipid-Lowering Responses to Dyslipidemia Determine the Efficacy on Liver Enzymes in Metabolic Dysfunction-Associated Fatty Liver Disease with Hepatic Injuries: A Prospective Cohort StudyDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2022; : 1173 doi: 10.2147/DMSO.S356371
67
Katherine T. Brunner, Cameron J. Henneberg, Robert M. Wilechansky, Michelle T. Long. Nonalcoholic Fatty Liver Disease and Obesity TreatmentCurrent Obesity Reports 2019; 8(3): 220 doi: 10.1007/s13679-019-00345-1
68
Michele Finotti, Maurizio Romano, Pasquale Auricchio, Michele Scopelliti, Marco Brizzolari, Ugo Grossi, Marco Piccino, Stefano Benvenuti, Giovanni Morana, Umberto Cillo, Giacomo Zanus. Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical AlternativesJournal of Personalized Medicine 2021; 11(6): 499 doi: 10.3390/jpm11060499
69
Zobair M. Younossi, Rohit Loomba, Mary E. Rinella, Elisabetta Bugianesi, Giulio Marchesini, Brent A. Neuschwander‐Tetri, Lawrence Serfaty, Francesco Negro, Stephen H. Caldwell, Vlad Ratziu, Kathleen E. Corey, Scott L. Friedman, Manal F. Abdelmalek, Stephen A. Harrison, Arun J. Sanyal, Joel E. Lavine, Philippe Mathurin, Michael R. Charlton, Naga P. Chalasani, Quentin M. Anstee, Kris V. Kowdley, Jacob George, Zachary D. Goodman, Keith Lindor. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitisHepatology 2018; 68(1): 361 doi: 10.1002/hep.29724
70
Henrik H. Hansen, Michael Feigh, Sanne S. Veidal, Kristoffer T. Rigbolt, Niels Vrang, Keld Fosgerau. Mouse models of nonalcoholic steatohepatitis in preclinical drug developmentDrug Discovery Today 2017; 22(11): 1707 doi: 10.1016/j.drudis.2017.06.007
71
Robert Gish, Jian-Gao Fan, Zahra Dossaji, Jeanne Fichez, Tooba Laeeq, Magnus Chun, Jerome Boursier. Review of current and new drugs for the treatment of metabolic-associated fatty liver diseaseHepatology International 2024; 18(S2): 977 doi: 10.1007/s12072-024-10698-y
72
Vasilios G. Athyros, Charalambos Koumaras, George Sfikas. Statins and Non-Alcoholic Fatty Liver Disease Progression: Further CommentsCurrent Vascular Pharmacology 2021; 19(6): 673 doi: 10.2174/1570161119666201215141414
73
Fabio Nascimbeni, Elisa Pellegrini, Simonetta Lugari, Alberto Mondelli, Serena Bursi, Giovanna Onfiani, Francesca Carubbi, Amedeo Lonardo. Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foesAtherosclerosis 2019; 284: 66 doi: 10.1016/j.atherosclerosis.2019.02.028
74
Somaya Albhaisi, Arun Sanyal. Recent advances in understanding and managing non-alcoholic fatty liver diseaseF1000Research 2018; 7: 720 doi: 10.12688/f1000research.14421.1
75
Yaron Rotman, Arun J Sanyal. Current and upcoming pharmacotherapy for non-alcoholic fatty liver diseaseGut 2017; 66(1): 180 doi: 10.1136/gutjnl-2016-312431
76
Maria Apostolopoulou, Michael Roden. Nicht-alkoholische Fettlebererkrankung2022; : 211 doi: 10.1007/978-3-662-62484-5_20
77
Ma Ai Thanda Han, Osama Altayar, Shadi Hamdeh, Varun Takyar, Yaron Rotman, Ohad Etzion, Eric Lefebvre, Rifaat Safadi, Vlad Ratziu, Larry J. Prokop, Mohammad Hassan Murad, Mazen Noureddin. Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology 2019; 17(4): 616 doi: 10.1016/j.cgh.2018.06.011
78
Katsutoshi Tokushige, Kenichi Ikejima, Masafumi Ono, Yuichiro Eguchi, Yoshihiro Kamada, Yoshito Itoh, Norio Akuta, Masato Yoneda, Motoh Iwasa, Masashi Yoneda, Motoyuki Otsuka, Nobuharu Tamaki, Tomomi Kogiso, Hiroto Miwa, Kazuaki Chayama, Nobuyuki Enomoto, Tooru Shimosegawa, Tetsuo Takehara, Kazuhiko Koike. Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020Hepatology Research 2021; 51(10): 1013 doi: 10.1111/hepr.13688
79
May G. Akl, Scott B. Widenmaier. Immunometabolic factors contributing to obesity-linked hepatocellular carcinomaFrontiers in Cell and Developmental Biology 2023; 10 doi: 10.3389/fcell.2022.1089124
80
Athanasia Mitsala, Christos Tsalikidis, Konstantinos Romanidis, Michail Pitiakoudis. Non-Alcoholic Fatty Liver Disease and Extrahepatic Cancers: A Wolf in Sheep’s Clothing?Current Oncology 2022; 29(7): 4478 doi: 10.3390/curroncol29070356
81
Niki Katsiki, Vasilios G Athyros. Non-alcoholic steatohepatitis and type 2 diabetes mellitus: the effects of weight loss versus drug treatmentCurrent Medical Research and Opinion 2019; 35(7): 1305 doi: 10.1080/03007995.2019.1589152
82
Ismini Tzanaki, Aris P Agouridis, Michael S Kostapanos. Is there a role of lipid-lowering therapies in the management of fatty liver disease?World Journal of Hepatology 2022; 14(1): 119-139 doi: 10.4254/wjh.v14.i1.119
83
Frank Tacke. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosisExpert Opinion on Investigational Drugs 2018; 27(3): 301 doi: 10.1080/13543784.2018.1442436
84
Vasilios G. Athyros, Dimitri P. Mikhailidis. High incidence of metabolic syndrome further increases cardiovascular risk in patients with type 2 diabetes. Implications for everyday practiceJournal of Diabetes and its Complications 2016; 30(1): 9 doi: 10.1016/j.jdiacomp.2015.07.012
85
Abdul M. Oseini, Arun J. Sanyal. Therapies in non‐alcoholic steatohepatitis (NASH)Liver International 2017; 37(S1): 97 doi: 10.1111/liv.13302
86
Nicholas W. S. Chew, Cheng Han Ng, Mark Dhinesh Muthiah, Arun J. Sanyal. Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular DiseaseCurrent Atherosclerosis Reports 2022; 24(7): 515 doi: 10.1007/s11883-022-01027-5
87
Maria-Styliani Kalogirou, Dimitrios Patoulias, Anna-Bettina Haidich, Evangelos Akriviadis, Emmanouil Sinakos. Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trialsClinics and Research in Hepatology and Gastroenterology 2021; 45(3): 101568 doi: 10.1016/j.clinre.2020.10.012
88
Gregor Lorbek, Žiga Urlep, Damjana Rozman. Pharmacogenomic and Personalized Approaches to Tackle Nonalcoholic Fatty Liver DiseasePharmacogenomics 2016; 17(11): 1273 doi: 10.2217/pgs-2016-0047
89
Scott Isaacs. Nonalcoholic Fatty Liver DiseaseEndocrinology and Metabolism Clinics of North America 2023; 52(1): 149 doi: 10.1016/j.ecl.2022.06.007
90
Vasilios G. Athyros, Konstantinos Tziomalos, Asterios Karagiannis. Statins for Improving Myocardial Perfusion in Patients With Nonalcoholic Fatty Liver Disease Undergoing Percutaneous Coronary InterventionThe American Journal of Cardiology 2016; 117(2): 311 doi: 10.1016/j.amjcard.2015.11.001
91
Nikos Lazaridis, Emmanuel Tsochatzis. Current and future treatment options in non-alcoholic steatohepatitis (NASH)Expert Review of Gastroenterology & Hepatology 2017; 11(4): 357 doi: 10.1080/17474124.2017.1293523
92
Stefano Ciardullo, Gianluca Perseghin. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetesMetabolism 2021; 121: 154752 doi: 10.1016/j.metabol.2021.154752
93
Bo Zhu, Hao Wu, Kathryn S. Li, Shahram Eisa-Beygi, Bandana Singh, Diane R. Bielenberg, Wendong Huang, Hong Chen. Two sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosisVascular Pharmacology 2024; 154: 107249 doi: 10.1016/j.vph.2023.107249
94
Connie B. Newman. Safety of Statins and Nonstatins for Treatment of DyslipidemiaEndocrinology and Metabolism Clinics of North America 2022; 51(3): 655 doi: 10.1016/j.ecl.2022.01.004
95
Eric P. Stahl, Devinder S. Dhindsa, Suegene K. Lee, Pratik B. Sandesara, Naga P. Chalasani, Laurence S. Sperling. Nonalcoholic Fatty Liver Disease and the HeartJournal of the American College of Cardiology 2019; 73(8): 948 doi: 10.1016/j.jacc.2018.11.050
96
Xiao-Hui Fang, Cai-E Wang, Jiao Deng, Xing-Shun Qi. Statins for treatment of fatty liver disease: Recent advancesWorld Chinese Journal of Digestology 2023; 31(16): 659 doi: 10.11569/wcjd.v31.i16.659
Abstract() |  Core Tip() |  Full Article(HTML)() | Times Cited  (0) | Total Visits (0) | Open
97
Mark D. Muthiah, Arun J. Sanyal. Current management of non‐alcoholic steatohepatitisLiver International 2020; 40(S1): 89 doi: 10.1111/liv.14355
98
Theodora Griva, Chrysoula Boutari, Konstantinos Tziomalos, Michael Doumas, Asterios Karagiannis, Vasilios G. Athyros. Arterial Stiffness and Nonalcoholic Fatty Liver Disease: Which is the Chicken and Which is the Egg?The Open Hypertension Journal 2017; 9(1): 1 doi: 10.2174/1876526201709010001
99
Vasilios G Athyros. Statins for the Treatment of Non Alcoholic Fatty Liver Disease in Patients with Metabolic SyndromeJournal of Diabetes, Metabolic Disorders & Control 2016; 3(1) doi: 10.15406/jdmdc.2016.03.00057
100
Mohamed Abdallah, Landon Brown, John Provenza, Raseen Tariq, Smitha Gowda, Ashwani K. Singal. Safety and efficacy of dyslipidemia treatment in NAFLD patients: a meta-analysis of randomized controlled trialsAnnals of Hepatology 2022; 27(6): 100738 doi: 10.1016/j.aohep.2022.100738
101
Practical Diabetes Care2018; : 387 doi: 10.1002/9781119052210.ch13
102
V. G. Athyros, N. Katsiki, D. P. Mikhailidis. Letter: statins and cirrhosisAlimentary Pharmacology & Therapeutics 2017; 46(11-12): 1123 doi: 10.1111/apt.14355
103
Vimala Ananthy, Raman Palanyswamy Priyadharsini, Umamaheswari Subramanian. Pathogenesis, Diagnosis, and Management of Metabolic Syndrome: A Comprehensive ReviewSBV Journal of Basic, Clinical and Applied Health Science 2021; 4(2): 39 doi: 10.5005/jp-journals-10082-03111
104
Mohamad Kareem Marrache, Don C. Rockey. Statins for treatment of chronic liver diseaseCurrent Opinion in Gastroenterology 2021; 37(3): 200 doi: 10.1097/MOG.0000000000000716
105
George Zacharia, Anu Jacob, Manivarnan Karichery, Abhishek Sasidharan. Impact of statins in the liver: A bane or a boon?Canadian Liver Journal 2024;  doi: 10.3138/canlivj-2023-0028
106
Satoshi Shinozaki, Toshiyuki Tahara, Kouichi Miura, Alan Kawarai Lefor, Hironori Yamamoto. Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: A Pilot StudyLife 2023; 13(6): 1327 doi: 10.3390/life13061327
107
Umair Iqbal, Brandon J. Perumpail, Nimy John, Sandy Sallam, Neha D. Shah, Waiyee Kwong, George Cholankeril, Donghee Kim, Aijaz Ahmed. Judicious Use of Lipid Lowering Agents in the Management of NAFLDDiseases 2018; 6(4): 87 doi: 10.3390/diseases6040087
108
Chrysoula Boutari, Panagiotis D. Pappas, Dimitrios Anastasilakis, Christos S. Mantzoros. Statins’ efficacy in non-alcoholic fatty liver disease: A systematic review and meta-analysisClinical Nutrition 2022; 41(10): 2195 doi: 10.1016/j.clnu.2022.08.001
109
Rashid Ali Khan, Uma Bhandari, Prem Kapur, Abhinav Jain, Farrukh Farah. Effects of rosuvastatin (added to hypocaloric diet) on serum periostin, adiponectin, proinflammtory cytokines levels and hepatic steatosis in non-alcoholic fatty liver disease patients with dyslipidemiaClinical Epidemiology and Global Health 2019; 7(1): 53 doi: 10.1016/j.cegh.2017.12.010
110
Sergi Guixé-Muntet, Chang-Peng Zhu, Wei-Fen Xie, Jordi Gracia-Sancho. Novel therapeutics for portal hypertension and fibrosis in chronic liver diseasePharmacology & Therapeutics 2020; 215: 107626 doi: 10.1016/j.pharmthera.2020.107626
111
Caroline Chong Nguyen, Denis Duboc, Dominique Rainteau, Harry Sokol, Lydie Humbert, Philippe Seksik, Adèle Bellino, Hendy Abdoul, Naïm Bouazza, Jean-Marc Treluyer, Malika Saadi, Karim Wahbi, Heithem Soliman, Benoit Coffin, André Bado, Maude Le Gall, Olivier Varenne, Henri Duboc. Circulating bile acids concentration is predictive of coronary artery disease in humanScientific Reports 2021; 11(1) doi: 10.1038/s41598-021-02144-y
112
Emir Muzurović, Brigita Smolović, Snežana Vujošević, Milan Petakov. Editorial on Prevalence, Diagnosis and Treatment with 3 Different Statins of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?Current Vascular Pharmacology 2021; 19(5): 582 doi: 10.2174/1570161118666201008162537
113
C. Moctezuma-Velázquez. Tratamiento actual de la enfermedad por hígado graso no alcohólicoRevista de Gastroenterología de México 2018; 83(2): 125 doi: 10.1016/j.rgmx.2017.10.003
114
Matthew Kappus, Manal Abdelmalek. De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver TransplantationClinics in Liver Disease 2017; 21(2): 321 doi: 10.1016/j.cld.2016.12.006
115
David Niederseer, Bernhard Wernly, Elmar Aigner, Felix Stickel, Christian Datz. NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic ConsiderationsJournal of Clinical Medicine 2021; 10(3): 467 doi: 10.3390/jcm10030467
116
Prashanth Francis, Lisa M. Forman. Statins Show Promise Against Progression of Liver DiseaseClinical Liver Disease 2021; 18(6): 280 doi: 10.1002/cld.1143
117
Vasilios G. Athyros, Niki Katsiki, Dimitri P. Mikhailidis. Statins and non-alcoholic steatohepatitisMetabolism 2017; 66: e1 doi: 10.1016/j.metabol.2016.10.006
118
Atul D. Bali, Akiva Rosenzveig, William H. Frishman, Wilbert S. Aronow. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or AssociationCardiology in Review 2024; 32(5): 453 doi: 10.1097/CRD.0000000000000537
119
Michael Doumas, Konstantinos Imprialos, Konstantinos Stavropoulos, Vasilios G. Athyros. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?Current Vascular Pharmacology 2019; 17(5): 425 doi: 10.2174/157016111705190703102816
120
Carlos Moctezuma-Velázquez, Juan G. Abraldes, Aldo J. Montano-Loza. The Use of Statins in Patients With Chronic Liver Disease and CirrhosisCurrent Treatment Options in Gastroenterology 2018; 16(2): 226 doi: 10.1007/s11938-018-0180-4
121
Kensuke Kitsugi, Hidenao Noritake, Moe Matsumoto, Tomohiko Hanaoka, Masahiro Umemura, Maho Yamashita, Shingo Takatori, Jun Ito, Kazuyoshi Ohta, Takeshi Chida, Takafumi Suda, Kazuhito Kawata. Simvastatin inhibits hepatic stellate cells activation by regulating the ferroptosis signaling pathwayBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2023; 1869(7): 166750 doi: 10.1016/j.bbadis.2023.166750